Plasma Fractionation Market Size, Global Trends and Regional Insights to 2032
The plasma
fractionation market is poised for significant growth over the coming
years, driven by the increasing demand for plasma-derived therapies,
advancements in medical technologies, and the rising prevalence of chronic
diseases and rare conditions requiring immunoglobulin therapies. Plasma
fractionation refers to the process of separating blood plasma into its various
components, which are then used in the production of life-saving medications,
including immunoglobulins, clotting factors, and albumin. These therapies play
a vital role in treating disorders such as hemophilia, autoimmune diseases, and
immune deficiencies.
Plasma fractionation is a highly specialized process, and
its demand is closely tied to the increasing number of patients requiring
plasma-derived therapies. This has been further propelled by growing awareness
regarding rare diseases, the rising elderly population, and expanding
healthcare infrastructure. The market is also benefiting from technological
innovations in plasma separation techniques, making the process more efficient,
scalable, and cost-effective.
Get a Free Sample Copy - https://www.skyquestt.com/sample-request/plasma-fractionation-market
Market Size & Forecast
The global plasma fractionation market was valued at USD
36.2 billion in 2024 and is expected to grow at a compound annual growth rate
(CAGR) of 8.3% from 2025 to 2032. By 2032, the market is projected to reach USD
68.52 billion. This growth trajectory is driven by increasing therapeutic
demand, the development of advanced fractionation technologies, and an
expanding focus on improving healthcare outcomes in emerging regions.
Key Market Drivers
1. Growing Prevalence of Chronic Diseases and
Hematological Disorders: Chronic conditions such as immune deficiencies,
hemophilia, and autoimmune diseases have significantly contributed to the
rising demand for plasma-derived therapies. Immunoglobulins and clotting
factors are critical in treating such conditions, fostering the expansion of
the plasma fractionation market.
2. Advancements in Plasma Fractionation Technologies:
Continued advancements in fractionation technologies, such as the development
of better protein separation methods, have improved the efficiency and yield of
plasma-derived products. New technologies also minimize the potential risks
associated with the process, further enhancing the market's growth potential.
3. Increasing Healthcare Expenditure and Infrastructure
Development: In many regions, particularly in emerging markets, increasing
healthcare expenditure and improved infrastructure are enabling better access
to plasma-derived therapies. This has led to a rise in the demand for these
therapies, which in turn drives the need for more plasma fractionation.
4. Aging Population: The growing aging population
globally is a key factor in the market’s expansion. Elderly individuals are
more prone to developing chronic diseases that require the use of
plasma-derived treatments, particularly for immune and clotting disorders,
which bolsters market demand.
5. Rise in Plasma Donation Initiatives: Increasing
plasma donation programs in several countries, coupled with better awareness
and incentives for donors, has enhanced the supply of plasma for fractionation.
This has contributed to the growth of the market as manufacturers seek to
ensure a steady supply of plasma for fractionation.
Market Restraints
1. High Cost of Plasma-Derived Therapies:
Plasma-derived products, particularly immunoglobulins, can be expensive to
produce, which may limit access to these treatments in low-income regions. This
poses a challenge to the widespread adoption of plasma therapies, especially in
resource-constrained environments.
2. Stringent Regulatory Requirements: Plasma
fractionation is subject to stringent regulatory controls due to the need for
high-quality, safe, and effective therapies. Regulatory hurdles can sometimes
delay the launch of new products or innovations in the market.
3. Ethical Concerns Regarding Plasma Donation:
Ethical concerns regarding the exploitation of donors and the safety of plasma
collection have raised challenges in some regions, especially when donor
recruitment methods are not transparent. Addressing these concerns is critical
to maintaining the public’s trust and confidence in the plasma fractionation
process.
Make an Inquiry to Address your Specific Business Needs
- https://www.skyquestt.com/speak-with-analyst/plasma-fractionation-market
Segmentation Analysis
1. By Product Type:
- Immunoglobulins:
This segment is expected to dominate the market during the forecast period.
Immunoglobulins are primarily used in the treatment of immunodeficiencies and
autoimmune disorders.
- Clotting
Factors: Clotting factors, including Factor VIII and Factor IX, are
critical in the treatment of hemophilia and other bleeding disorders.
- Albumin:
Albumin is used in critical care and surgery, particularly for patients
experiencing severe burns, trauma, or liver diseases.
- Other
Plasma-Derived Products: This includes therapies like fibrinogen and
alpha-1 antitrypsin.
2. By Technology:
- Chromatography:
This method is increasingly being adopted due to its ability to efficiently
separate proteins based on their chemical properties, enhancing the purity of
the final products.
- Centrifugation:
A traditional and widely used technique, centrifugation involves spinning
plasma at high speeds to separate its components based on density.
- Filtration:
Filtration technologies are being integrated to enhance the safety and quality
of plasma-derived therapies.
3. By End-User:
- Hospitals and
Clinics: The largest segment, as plasma-derived therapies are predominantly
administered in healthcare settings.
- Research
Institutes: Growing interest in research surrounding plasma-derived
therapies for emerging therapeutic applications.
- Others:
This includes blood centers and plasma donation centers, which also play a
crucial role in the market.
Regional Analysis
1. North America: North America holds the largest
share of the plasma fractionation market, driven by high healthcare spending,
advanced healthcare infrastructure, and widespread access to plasma-derived
therapies. The U.S. is a dominant player in the global plasma fractionation
market due to its strong healthcare sector and robust demand for plasma-derived
products.
2. Europe: Europe is another significant region, with
countries like Germany, the UK, and France leading the demand for plasma
fractionation. The rising prevalence of chronic diseases, along with increased
research and development activities, further boosts market growth in this
region.
3. Asia-Pacific: The Asia-Pacific region is expected
to witness the highest growth rate during the forecast period. Rising
healthcare awareness, improving medical infrastructure, and increasing
disposable income are driving the demand for plasma-derived therapies in countries
like China, India, and Japan.
4. Rest of the World: Latin America, the Middle East,
and Africa are gradually adopting plasma fractionation technologies, with
improving healthcare systems and increased plasma donation programs
contributing to market expansion in these regions.
Take Action Now: Secure Your Plasma Fractionation Market
Today - https://www.skyquestt.com/buy-now/plasma-fractionation-market
Competitive Landscape
The plasma fractionation market is highly competitive, with
major players such as Grifols, CSL Behring, Takeda Pharmaceutical Company
Limited, Octapharma, and Shire (now part of Takeda) dominating the market.
These companies are focusing on strategic mergers, acquisitions, and product
innovations to expand their market share. Additionally, increased investment in
plasma collection centers and partnerships with hospitals and research
institutes are key strategies employed by these companies to strengthen their
market presence.
Top Player’s Company Profiles in Plasma Fractionation
Industry
1.
CSL Behring (Australia)
2.
Grifols (Spain)
3.
Octapharma (Switzerland)
4.
Kedrion (Italy)
5.
China Biologic Products Holdings (China)
6.
Sanquin (Netherlands)
7.
Bio Products Laboratory (UK)
8.
Japan Blood Products Organization (Japan)
9.
LFB Group (France)
10.
Shanghai RAAS Blood Products (China)
11.
Green Cross Corporation (South Korea)
12.
Baxter International Inc. (US)
13.
Takeda Pharmaceutical Company Limited (Japan)
14.
Beijing Tiantan Biological Products (China)
15.
Biotest AG (Germany)
16.
China National Pharmaceutical Group Co.
(Sinopharm) (China)
17.
GC Pharma (South Korea)
18.
ADMA Biologics (US)
19.
Emergent BioSolutions (US)
20.
Renishaw plc (UK)
21.
HP Inc. (USA)
Read Plasma Fractionation Market Report Today - https://www.skyquestt.com/report/plasma-fractionation-market
Comments
Post a Comment